Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective

INTRODUCTION: This study assessed the cost-effectiveness of secukinumab compared with other biologics (adalimumab, infliximab, ustekinumab, ixekizumab, guselkumab, and Yisaipu [etanercept biosimilar]) for moderate-to-severe plaque psoriasis from the Chinese healthcare system perspective. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jinsui, Xia, Zemin, Guo, Wanjie, Ren, Xiaoxiao, Liu, Fang, Ratnaparkhi, Gargi, Pagada, Amit, Subramanian, Subhashini, Hu, Min, Chen, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613169/
https://www.ncbi.nlm.nih.gov/pubmed/37741954
http://dx.doi.org/10.1007/s13555-023-01041-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613169/
https://www.ncbi.nlm.nih.gov/pubmed/37741954
http://dx.doi.org/10.1007/s13555-023-01041-8

Ejemplares similares